Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
10:41am, Monday, 01'st Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Boston Partners Has $27.93 Million Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX
04:04am, Friday, 28'th Nov 2025
Boston Partners raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 0.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Excha
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
08:03am, Monday, 24'th Nov 2025
CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of “Buy” by Brokerages
03:46am, Saturday, 22'nd Nov 2025
Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX - Get Free Report) have received an average rating of "Buy" from the ten brokerages that are covering the firm, MarketBeat.com reports. Two inves
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:46am, Wednesday, 19'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
08:03am, Wednesday, 19'th Nov 2025
Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution
Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
08:03am, Tuesday, 18'th Nov 2025
CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Connor Clark & Lunn Investment Management Ltd. Sells 66,267 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
04:36am, Monday, 17'th Nov 2025
Connor Clark and Lunn Investment Management Ltd. cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 41.1% in the second quarter, according to the company in its most recent di
Allworth Financial LP Raises Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX
03:33am, Monday, 17'th Nov 2025
Allworth Financial LP lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 7,754.7% during the undefined quarter, according to its most recent filing with the Securities a
CPRX vs. ZTS: Which Stock Is the Better Value Option?
12:41pm, Thursday, 13'th Nov 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
Wall Street Analysts Believe Catalyst (CPRX) Could Rally 51.45%: Here's is How to Trade
10:56am, Thursday, 13'th Nov 2025
The consensus price target hints at a 51.5% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
10:51am, Thursday, 13'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
10:41am, Thursday, 13'th Nov 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2025 Earnings Call Transcript
08:36pm, Thursday, 06'th Nov 2025
Catalyst Pharmaceuticals, Inc. ( CPRX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Michael Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Direct
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
11:46am, Thursday, 06'th Nov 2025
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
